血管内皮生长因子抑制剂治疗视网膜血管瘤样增生药理及临床研究进展
Advances in pharmacological and clinical studies of vascular endothelial growth factor inhibitors in the treatment of retinal angiomatous proliferation
曾春琴 1沈强 1胡高铭1
作者信息
- 1. 重庆大学附属江津医院眼科,重庆 402260
- 折叠
摘要
视网膜血管瘤样增生(retinal angiomatous proliferation,RAP)是一种血管增生导致的眼科疾病,因血管生长因子及血管抑制因子失衡,促使微血管瘤形成,可严重影响患者视力.高表达的血管内皮生长因子(vascular endothelial growth factor,VEGF)可加快RAP发生发展,抗VEGF可加快瘤体萎缩而改善临床疗效.现阶段已知的抗VEGF药物包括雷珠单抗(ranibizumab)、贝伐珠单抗(bevacizumab)及阿柏西普(aflibercept)等.近年来,抗VEGF药物在RAP治疗中的作用备受关注,现对VEGF在RAP中的作用机制及抗VEGF治疗进展作一综述,旨在为临床提供参考.
Abstract
Retinal angiomatous proliferation(RAP)is a type of eye disease caused by angiogenesis.Microhemangioma is formed due to the imbalance of vascular growth factors and vascular inhibitory factors,which can seriously affect the visual acuity of patients.High expression of vascular endothelial growth factor(VEGF)can accelerate the development of RAP,and anti-VEGF can accelerate tumor atrophy and improve clinical efficacy.Currently,known anti-VEGF drugs include ranibizumab,bevacizumab and aflibercept,etc.In recent years,the role of anti-VEGF in RAP therapy has attracted much attention.This article reviewed the mechanism of VEGF in RAP and the progress of anti-VEGF therapy,aiming to provide clinical reference.
关键词
血管内皮生长因子/视网膜血管瘤样增生/雷珠单抗/贝伐珠单抗Key words
vascular endothelial growth factor/retinal angiomatous hyperplasia/ranibizumab/bevacizumab引用本文复制引用
基金项目
重庆市江津区2020年度科技计划项目(Y2020063)
出版年
2024
NETL
NSTL
万方数据